|
FY2025
12 months to Jan 31, 2026
|
FY2024
12 months to Jan 31, 2025
|
FY2023
12 months to Jan 31, 2024
|
FY2022
12 months to Jan 31, 2023
|
FY2021
12 months to Jan 31, 2022
|
|
|---|---|---|---|---|---|
| Net sales and revenue | |||||
| Cost of sales (includes $86.4 million, $99.2 million and $117.0 million with related parties for the years ended January 31, 2026, 2025 and 2024, respectively) | |||||
| Gross profit | |||||
| Selling, general and administrative expenses | |||||
| Equity in income of unconsolidated affiliates | |||||
| Interest and other income, net | |||||
| Income before income taxes | |||||
| Benefit (provision) for income taxes | |||||
| Net income | |||||
| Net income attributable to noncontrolling interests | |||||
| Net income attributable to REX common shareholders | |||||
| Weighted average shares outstanding – basic (in Shares) | |||||
| Basic net income per share from continuing operations attributable to REX common shareholders (in Dollars per share) | |||||
| Basic net income per share attributable to REX common shareholders (in Dollars per share) | |||||
| Weighted average shares outstanding – diluted (in Shares) | |||||
| Diluted net income per share from continuing operations attributable to REX common shareholders (in Dollars per share) | |||||
| Diluted net income per share attributable to REX common shareholders (in Dollars per share) | |||||
Loading...